Insulet Corporation
Insulet Corporation Amends Credit Agreement
Summary
On August 2, 2024, Insulet Corporation amended its Credit Agreement to replace existing term loans with new term loans, extend the maturity date from May 4, 2028, to August 2, 2031, and adjust the interest rates. The new term loans have an interest rate margin of 1.50% for base rate loans and 2.50% for term SOFR loans, with a SOFR floor of 0.00%. The revolving credit facility interest rate margin was also reduced. Wachtell, Lipton, Rosen & Katz advised the company on the transaction.
Profitelligence Alerts
Get alerts for PODD
Be first to know when Insulet Corporation files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Insulet Corporation
Insulet Corporation is a prominent healthcare company specializing in medical devices, with a key focus on diabetes management. Its flagship product, the Omnipod Insulin Management System, is an innovative, tubeless insulin pump that offers users freedom and flexibility, addressing the lifelong needs of individuals with diabetes. The system is acclaimed for its discreet, water-resistant pods, which deliver continuous insulin delivery without the constraints of traditional insulin pumps. Insulet Corporation plays a crucial role in the medical technology industry by enhancing patient experiences and outcomes. Headquartered in Acton, Massachusetts, Insulet Corporation continues to pioneer advancements in insulin delivery solutions, directly impacting healthcare providers and improving the quality of life for diabetes patients globally. Its market significance is underscored by its commitment to innovation and accessibility, bridging the gap between technology and patient-centric care in the rapidly evolving healthcare sector.
Official SEC Documents
Advertisement